Associations of severe COVID-19 with polypharmacy in the REACT-SCOT case-control study

Paul M McKeigue ¹ ³ , Sharon Kennedy ⁷ , Amanda Weir ³ , Jen Bishop ³ , Stuart J McGurnaghan ² , David McAllister ⁴ ³ , Chris Robertson ⁵ ³ , Rachael Wood ⁷ , Nazir Lone ¹ , Janet Murray ³ , Thomas M Caparrotta ² , Alison Smith-Palmer ³ , David Goldberg ³ , Jim McMenamin ³ , Colin Ramsay ³ , Bruce Guthrie ¹ , Sharon Hutchinson ⁶ ³ , Helen M Colhoun ² ³

Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Teviot
 Place, Edinburgh EH8 9AG, Scotland. PM - Professor of Genetic Epidemiology and Statistical Genetics.
 NL - Clinical Senior Lecturer in Critical Care

2 Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Western General Hospital Campus, Crewe Road, Edinburgh EH4 2XUC, Scotland. HC - Axa Chair in Medical Informatics and Epidemiology. TC - Sir George Alberti Doctoral Fellow in Pharmacoepidemiology.

3 Public Health Scotland, Meridian Court, 5 Cadogan Street, Glasgow G2 6QE

4 Institute of Health and Wellbeing, University of Glasgow, 1 Lilybank Gardens, Glasgow G12 8RZ.

DM - Wellcome Trust Intermediate Clinical Fellow and Beit Fellow

5 Department of Mathematics and Statistics, University of Strathclyde, 16 Richmond Street, Glasgow G1 1XQ. CR - Professor of Public Health Epidemiology

6 School of Health and Life Sciences, Glasgow Caledonian University. SH - Professor of Epidemiology and Population Health

7 NHS Information Services Division (Public Health Scotland), Gyle Square, 1 South Gyle Crescent,Edinburgh, EH12 9EB. RW - Consultant in Maternal and Child Health.

On behalf of Public Health Scotland COVID-19 Health Protection Study Group.

Abstract

Objectives – To investigate the relation of severe COVID-19 to prior drug prescribing.

Design – Matched case-control study (REACT-SCOT) based on record linkage to hospital discharges since June 2015 and dispensed prescriptions issued in primary care during the last 240 days.

Setting – Scottish population.

Main outcome measure – Severe COVID-19, defined by entry to critical care or fatal outcome.

Participants – All 4272 cases of severe COVID-19 in Scotland since the start of the epidemic, with 36948 controls matched for age, sex and primary care practice.

Results – Severe COVID-19 was strongly associated with the number of non-cardiovascular drug classes dispensed. This association was strongest in those not resident in care homes, in whom the rate ratio (95% CI) associated with dispensing of 12 or more drug classes versus none was 10.8 (8.7, 13.2), and was not accounted for by treatment of conditions designated as conferring increased risk. Of 17 drug classes postulated at the start of the epidemic to be "medications compromising COVID", all were associated with increased risk of severe COVID-19. The largest effect was for antipsychotic agents: rate ratio 4.14 (3.39, 5.07). Other drug classes with large effects included proton pump inhibitors (rate rato 2.19 (1.70, 2.80) for ≥ 2 defined daily doses/day), opioids (3.62 (2.65, 4.94) for ≥ 50 mg morphine equivalent/day) and gabapentinoids. These associations persisted after adjusting for covariates, and were stronger with recent than with non-recent exposure.

Conclusions – Severe COVID-19 is associated with polypharmacy and with drugs that cause sedation, respiratory depression or dyskinesia, have anticholinergic effects or affect the gastrointestinal system. These associations are not easily explained by co-morbidity. Although the evidence for causality is not conclusive, these results support existing guidance on reducing overprescribing of these drug classes and limiting inappropriate polypharmacy as a potential means of reducing COVID-19 risk.

Registration – ENCEPP number EUPAS35558

What is already known on this topic – Two previous studies have examined the relationship of severe COVID-19 to drugs for the cardiovascular system. This is the first systematic study of the relationship of severe COVID-19 to prior drug prescribing.

What this study adds – Severe COVID-19 is associated with polypharmacy and with drugs that cause sedation, respiratory depression or dyskinesia, have anticholinergic effects or affect the gastrointestinal system. These associations are not easily explained by co-morbidity. These results support earlier warnings that these drug classes that these drugs might increase susceptibility to COVID-19, and reinforce existing guidance on reducing overprescribing of these drug classes.

Background

In the initial analysis of REACT-SCOT, a matched case control study of risk factors for severe COVID-19 in Scotland, we reported a strong association of severe COVID-19 with having had at least one prescription dispensed in the past year¹. The univariate rate ratios associated with at least one prescription varied from 3.8 in those aged under 60 years to 2.3 in those aged 75 years and over. This association persisted after adjusting for care home residence, hospital admission in the last five years, and diagnoses of conditions designated by public health agencies as conferring vulnerability to COVID-19 (hereafter listed conditions). The objective of this study was to investigate this association.

Methods

The design of the REACT-SCOT case-control study has been described in detail elsewhere¹. As this study was set up in response to a national emergency no arrangements were made for patient and public involvement. All individuals testing positive for nucleic acid for SARS-CoV-2 in Scotland were ascertained through the Electronic Communication of Surveillance in Scotland (ECOSS) database. Admissions to critical care were obtained from the Scottish Intensive Care Society and Audit Group (SICSAG) database that captures admission to all critical care (intensive care or high dependency) units. Death registrations were obtained from linkage to the National Register of Scotland. Severe or fatal COVID-19 was defined by either (1) a positive nucleic acid test followed by entry to critical care or death within 28 days; or (2) a death certificate with COVID-19 as underlying cause.

For each case, the Community Health Index database was used to select up to ten controls matched for sex, one-year age band and registered with the same primary care practice, who were alive on the same day as the first date that the case tested positive. For fatal cases who had not tested positive, the incident date was assigned as 14 days before death. For this analysis based on ascertainment of positive test results up to 6 June 2020, entry to critical care up to 14 June 2020 and deaths up to 12 June 2020 there were 4272 cases and 36948 controls.

Morbidity and drug prescribing

For all cases and controls, ICD-10 diagnostic codes were extracted from the last five years of hospital discharge records in the Scottish Morbidity Record (SMR01), excluding records of discharges less than 25 days before testing positive for SARS-CoV-2, and from the national cancer registry. Diagnoses of diabetes were extracted from linkage to the national diabetes register. British National Formulary (BNF) drug codes for dispensed prescriptions issued in primary care were extracted from the Scottish Prescribing Information System². A cutoff date of 15 days before the incident date (date of testing positive for SARS-CoV-2, or 14 days before death for fatal cases without a positive test) was set, and prescriptions dispensed in a 240-day interval before this cutoff date were included. For this analysis prescription codes from BNF chapters 14 and above, comprising dressings, appliances, vaccines, anaesthesia and other preparations were grouped as "Other".

We began by testing for association of severe COVID-19 with the number of drug classes (BNF subparagraph codes) for which at least one prescription had been dispensed during the period of observation. In accordance with earlier suggestions that prescribing of multiple cardiovascular drugs, which is supported by evidence-based guidelines, should be considered separately from putatively inappropriate polypharmacy³, we partitioned the number of drug classes dispensed into cardiovascular and other drugs. To define a prespecified hypothesis about drug classes postulated to increase the risk of severe COVID-19, we used a review by Laporte and Healy published on 2 April 2020 that listed 17 widely prescribed drug classes associated with increased pneumonia risk and therefore of concern as "medications compromising COVID"⁴. Excluding immunosuppressive drugs that are criteria for shielding, the Laporte-Healy list comprised proton pump inhibitors, gastrointestinal antispasmodics, H1 antihistamines, hypnotics and sedatives, antipsychotic drugs, antidepressants, drugs used in nausea and vertigo, opioid analgesics, gabapentinoids, anti-epileptic drugs, antimuscarinic drugs used in parkinsonism, urinary antispasmodics, and non-steroidal anti-inflammatory drugs.

For proton pump inhibitors and opioids, it was possible to use equivalent doses to calculate a total dose for all drugs in the class. Defined daily doses (DDDs) of each proton pump inhibitor were obtained from the DDD/ATC Index of the WHO Collaborating Centre for Drug Statistics Methodology. Morphine milligram equivalents (MMEs) for opioids were obtained from the website of the Faculty of Pain Medicine of the Royal College of Anaesthestists. Average daily doses of proton pump inhibitors (as DDDs) and opioids (as MME) were calculated for each individual as the sum of (conversion factor \times strength \times quantity dispensed) divided by observation period. The dose of opioid was calculated as the sum over opioid-containing items in subparagraph 0407010 (nonopioid and compound preparations) and 0407020 (opioid analgesics).

As described previously, we derived indicator variables for a list of conditions that have been designated as risk conditions for COVID-19 by public health agencies⁵: diabetes, heart disease, asthma or chronic obstructive airway disease, chronic kidney disease, disabling neurological disease, liver disease and immunodeficiency or immunosuppression. ICD-10 diagnostic and BNF drug codes used to derive these conditions are available with the ENCEPP registration. Socioeconomic status was encoded as the quintile of the postcode-based Scottish Index of Multiple Deprivation (SIMD).

Statistical analysis

Rate ratios for severe COVID-19 (hereafter COVID-19) were estimated from conditional logistic regression models, implemented as Cox regression in the R function survival::clogit. To distinguish between causality and confounding, we used several approaches:

- Testing for consistency of association with drugs that have a similar mode of action across different indication groups
- Testing for a dose-response relationship and stratifying by age group
- Adjusting for prespecified covariates.
- Comparison between recent (last 120 days of observation) and less recent (1 June 2019 to 121 days before exposure) time windows of dispensing.

Results

Relation of severe COVID-19 to polypharmacy

Figure 1 shows that the rate of of severe COVID-19 increased steeply with the number of non-cardiovascular drug classes and decreased with the number of noncardiovascular drug classes dispensed. Table 1 shows that this association was restricted to those not resident in care homes. Supplementary Table S1 shows that among those not resident in care homes, the association of severed COVID-19 with number of non-cardiovascular drug classes dispensed was present both in those without any diagnosed listed condition and in those with at least one diagnosed listed condition.

Associations with specific drug classes

In order to identify specific drug classes associated with severe COVID-19, we examined the associations among those not resident in a care home and without any listed condition, as most people diagnosed with listed conditions such as asthma and diabetes are on medication for these conditions. Table 2 shows univariate associations of dispensing of at least one drug in each BNF subparagraph, filtered to show only drug classes with at least 50 exposed individuals and p < 0.001. The drug classes associated with severe COVID-19 include proton pump inhibitors, laxatives, multiple classes of drugs acting on the central nervous system, nutritional supplements, and non-steroidal anti-inflammatory drugs.

Table 3 shows associations of severe COVID-19 with dispensing of each of the drug classes on the Laporte-Healy list in those not resident in a care home. All drug classes on this list were associated with increased risk in univariate analyses (though the association with NSAIDS was stronger in Table 2 where listed conditions were excluded. This included all the drug classes listed by Laporte and Healy as having anticholinergic effects: H1 antihistamines, antidepressants, urinary antispasmodics, gastrointestinal antispasmodics, drugs for vertigo, antimuscarinic drugs used in the treatment of parkinsonism, and antiepileptic drugs.

In a multivariable regression, the strongest independent associations were with proton pump inhibitors, antihistamines, antipsychotic drugs, and opioid analgesics. In both univariate and multivariable analyses, the highest rate ratio was that associated with antipsychotic drugs. As others have noted⁴, the chemical structures and modes of action of drugs used in the treatment of nausea and vertigo overlap with those of antipsychotic drugs. Supplementary Table S2 shows the univariate associations of severe COVID-19 with specific drugs classified in these two subparagraphs of the BNF.

Across both groups of indications, phenothiazines and other drugs that are dopamine antagonists were strongly associated with increased rates of severe disease. Rate ratios were elevated both for phenothiazines and for second-generation antipsychotics: aripiprazole, olanzapine, risperidone and amrisulpride.

Time window analyses

Supplementary Table S3 shows for each drug class on the Laporte-Healy list the rate ratio associated with dispensing in the most recent 120-day time window, with dispensing only in the previous time window as reference category. Because most users of these drugs had dispensed prescriptions in both time windows, these analyses are based on relatively small numbers: the drug classes shown are restricted to those with at least 500 cases and controls exposed only in the earlier time window . For most of these drug classes shown, the rate ratio associated with recent exposure only is above 1, but only for opioid analgesics, and to some extent proton pump inhibitors and anxiolytics, does this association reach conventional levels of statistical significance.

Dose-response analyses

Supplementary Table S4 shows the relationship of severe COVID-19 to average daily doses of opioids (as MME) and proton pump inhibitors (as DDDs) over the 240-day observation period. For both these drug classes there were dose-response relationships, and for proton pump inhibitors this relationship was strongest in those aged less than 75 years. With unexposed as baseline, the univariate rate ratio associated with opioid use in this age group was 3.62 (2.65, 4.94) in those with average daily dose of more than 50 mg morphine equivalent (MME), reduced to 2.90 (2.04, 4.11) on adjusting for care home residence, SIMD quintile and any history of neoplasm. For proton pump inhibitors, the univariate rate ratio associated with average dose of 2 or more DDDs / day was 2.19 (1.70, 2.80), reduced to 1.98 (1.50, 2.60) by adjusting for care home residence, SIMD quintile, any diagnosis of ICD-10 codes K20-K31 (diseases of esophagus, stomach and duodenum), non-steroidal anti-inflammatory drugs, anti-platelet agents and anticoagulants.

Associations with other drug classes

Supplementary Tables S5 and S6 show associations with drug classes in BNF chapters 2 (cardiovascular) and 10 (musculoskeletal). These chapters were selected as of interest because because specific hypotheses

about possible effects of drugs in these chapters – ACE inhibitors⁶, anticoagulants⁷, and hydroxychloroquine⁸– have been proposed or discussed.

Table S5 shows associations with drugs for the cardiovascular system. Prescriptions of loop diuretics and anticoagulants were associated with elevated rate ratios for severe COVID-19 in univariate and multivariate analyses. Over all age groups combined, the univariate rate ratio associated with oral anticoagulants was reduced from 1.88 (1.66, 2.12) to 1.28 (1.12, 1.46) by adjustment for ischaemic heart disese, other heart disease and ever-use of a proton pump inhibitor. Of drug classes commonly used to treat hypertension, ACE inhibitors and angiotensin II receptor antagonists were associated with reduced risk of COVID-19.

Table S6 shows associations with drugs for the musculoskeletal system disaggregated by generic name, as the BNF groups all disease-modifying antirheumatic drugs under a single subparagraph code. All antirheumatic drugs were associated with elevated rate ratios for COVID-19. The univariate rate ratio associated with hydroxychloroquine sulfate was 2.10 (1.34, 3.28); adjustment for ever-use of a proton pump inhibitor reduced this to 1.80 (1.15, 2.82).

Discussion

We have shown that severe COVID-19 is associated with polypharmacy, defined by the number of drugs classes dispensed during the period of observation, in individuals without conditions designated as conferring high risk. The rate ratios of 5 to 7 associated with dispensing of more than 10 drug classes are larger than the ratio of about 2 for all-cause mortality associated with this level of polypharmacy in a systematic review⁹. Attempting to investigate associations with specific drugs with a hypothesis-free approach is difficult because many of the drug classes that are strongly associated with severe COVID-19, such as proton pump inhibitors, opioids and gabapentinoids, are indicators of overprescribing, recognized as such in the Scottish National Therapeutic Index of prescribing quality¹⁰.

To narrow the hypothesis space we tested a pre-specified list of drugs postulated at the start of the epidemic to increase risk of severe COVID-19, based on previously described associations with pneumonia or activity on relevant pathways, especially anticholinergic agents⁴. We have shown that all the drugs originally listed are associated with increased risk. Distinguishing between causality and confounding as possible explanations for the association of COVID-19 with these drug classes is difficult because drug exposures are not measured accurately, and the associations are likely to be confounded by other drugs, by co-morbidities and more generally by frailty and socioeconomic deprivation.

The strongest association was with antipsychotic drugs. As the recognized indications for these drugs are not known to be associated with susceptibility to severe COVID-19, there is no obvious explanation for this association other than causality. Further evidence favouring causality is that drugs prescribed for nausea that have similar chemical structures and mode of action to antipsychotic drugs show similar associations with severe COVID-19.

For both opioids and proton pump inhibitors, four criteria provide moderate but not conclusive evidence favouring causal explanations over confounding. There are strong dose-response relationships of COVID-19 to dispensed average daily dose. Adjustment for covariates pre-specified as likely to confound these associations reduces the effect size only slightly. The effect sizes are larger in younger individuals and when the analysis is restricted to those without any of the designated risk conditions for COVID-19. Among ever-exposed individuals, the rate ratios associated with dispensing only in the most recent time window were higher than the rate ratios associated with dispensing only in an earlier time window. The dose-response relationship of opioid use to COVID-19 is similar in magnitude to that reported for community-acquired pneumonia in a study of people receiving medical care through the Veterans Administration from 2000-2012¹¹. Although gabapentinoids are classified in the BNF under subparagraph 0408010 ("Control of epilepsy"), in Scotland they are widely used in combination with or as substitutes for opioid analgesics.

A limitation of this study is that we do not have morbidity data from primary care, which would include risk factors such as smoking and coding of presenting complaints. Another limitation is that it is not possible to capture hospital prescribing data which includes biologic agents that have immunosuppressive effects. Strengths of this study are that diagnoses are based on hospital discharge records coded to ICD-10 (rather than the SNOMED-CT codes used in primary care databases), and that drug exposure is based on dispensed rather than issued prescriptions.

The mechanisms postulated by Laporte and Healy for drugs to increase risk of severe COVID-19 include sedation, respiratory depression, respiratory dyskinesia and anticholinergic effects⁴. We note that as SARS-CoV-2 is at least partly an enteric infection¹² and the ACE2 receptor is expressed in the intestine, it is plausible that proton pump inhibitors and other drugs acting on the gastrointestinal tract could increase susceptibility to severe infection. It may be relevant to investigate these associations in other countries where COVID-19 epidemics have been especially severe and overprescribing of drug classes such as proton pump inhibitors^{13–15} or opioids¹⁶ has been reported previously.

We emphasize that because of the relationship of COVID-19 to polypharmacy, associations with specific drug classes cannot be studied without taking into account how those drug classes are related to

the profile of drug prescribing. Of those drug classes that are not on the Laporte-Healy list, there are strong univariate associations of severe COVID-10 with dispensing of antibiotics, laxatives and nutritional supplements. The associations with nutritional supplements is likely to be confounded by overprescribing. For ACE inhibitors and angiotensin-II receptor blockers, our results are consistent with other studies that have found no increased risk associated with these drugs^{6,17} and indeed suggest some protective effect may be possible. To explore this more fully will require access to other datasets where measurements of blood pressure and other covariates are available. The relation of anticoagulant use to COVID-19 is of interest because coagulopathy is a feature of severe disease⁷. Although in this study anticoagulants were associated with increased risk in univariate analysis, this association was reduced by adjusting for covariates including diagnosed heart disease and co-prescribing of proton pump inhibitors. Associations with disease-modifying antirheumatic drugs such as hydroxychloroquine are likely to be confounded by hospital-based prescribing of biologic anti-rheumatic drugs, which is not captured by record linkage in Scotland.

Conclusion

Severe COVID-19 is strongly associated with polypharmacy. This association is not easily explained by co-morbidity, and it is strongest in those without hospital diagnoses of conditions that confer high risk of disease. As a prediction of which drug classes would be associated with increased susceptibility to severe COVID-19, the Laporte-Healy list prepared at the start of the epidemic appears to be remarkably accurate. Many of the drug classes on this list are recognized indicators of overprescribing. The consistency of associations with drugs that have similar modes of action across different groups of indication, the dose-response and time window effects support causal explanations for at least some these associations. We recommend that public health agencies should reinforce existing guidelines on avoidance of overprescribing of these drug classes and more generally on inappropriate polypharmacy.

Declarations

Ethics approval and information governance

This study was conducted under approvals from the Public Benefit and Privacy Panel for Health and Social Care that allow Public Health Scotland staff to link datasets. Datasets were de-identified before analysis.

Data sharing

Requests for access to the data may be submitted to the Public Benefit and Privacy Panel.

Role of the funding source

This study was undertaken without any external funding.

Transparency declaration

PM, as the manuscript's guarantor, affirms: that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned and registered have been explained. This manuscript has been generated directly from the source data by a reproducible research pipeline. All source code used for derivation of variables, statistical analysis and generation of this manuscript is freely available on GitHub.

Registration

The study protocol was registered with the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCEPP number EUPAS35558).

Conflicts of interest

HC receives research support and honoraria and is a member of advisory panels or speaker bureaus for Sanofi Aventis, Regeneron, Novartis, Novo-Nordisk and Eli Lilly. HC receives or has recently received non-binding research support from AstraZeneca and Novo-Nordisk. SH received honoraria from Gilead.

Acknowledgements

We thank all staff in critical care units who submitted data to the SICSAG database, the Scottish Morbidity Record Data Team, the staff of the National Register of Scotland, the Public Health Scotland Terminology Services, the HPS COVID-19 Laboratory & Testing cell and the NHS Scotland Diagnostic Virology Laboratories, and Nicola Rowan (HPS) for coordinating this collaboration.

Public Health Scotland COVID-19 Health Protection Study Group

Alice Whettlock¹, Allan McLeod¹, Andrew Gasiorowski¹, Andrew Merrick¹, Andy McAuley¹, April Went¹, Calum Purdie¹, Colin Fischbacher¹, Colin Ramsay¹, David Bailey¹, David Henderson¹, Diogo Marques¹, Eisin McDonald¹, Genna Drennan¹, Graeme Gowans¹, Graeme Reid¹, Heather Murdoch¹, Jade Carruthers¹, Janet Fleming¹, Jade Carruthers¹, Joseph Jasperse¹, Josie Murray¹, Karen Heatlie¹, Lindsay Mathie¹, Lorraine Donaldson¹, Martin Paton¹, Martin Reid¹, Melissa Llano¹, Michelle Murphy-Hall¹, Paul Smith¹, Ros Hall¹, Ross Cameron¹, Susan Brownlie¹, Adam Gaffney², Aynsley Milne², Christopher Sullivan², Edward McArdle², Elaine Glass², Johanna Young², William Malcolm², Jodie McCoubrey²

1 Health Protection Scotland (Public Health Scotland), Meridian Court, 5 Cadogan Street, Glasgow G2 6QE.

2 NHS National Services Scotland, Meridian Court, 5 Cadogan Street, Glasgow G2 6QE.

Supplementary material

The R and Rmarkdown scripts used to generate this article, which include the code used to derive variables, will be made available when the paper is published.

References

1. McKeigue PM, Weir A, Bishop J, et al. Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study. medRxiv 2020;2020.05.28.20115394.

 Alvarez-Madrazo S, McTaggart S, Nangle C, Nicholson E, Bennie M. Data Resource Profile: The Scottish National Prescribing Information System (PIS). International Journal of Epidemiology 2016;45(3):714–715f.

3. Appleton SC, Abel GA, Payne RA. Cardiovascular polypharmacy is not associated with unplanned hospitalisation: Evidence from a retrospective cohort study. BMC family practice 2014;15:58.

4. Laporte J-R, Healy D. In the midst of the SARS-CoV-2 pandemia, caution is needed with drugs that increase the risk of pneumonia. Data-based Medicine Americas Ltd; 2020.

5. NHS. Who's at higher risk from coronavirus - Coronavirus (COVID-19). nhs.uk.

6. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. ReninAngiotensinAldosterone System

Blockers and the Risk of Covid-19. New England Journal of Medicine 2020;0(0):null.

7. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020;

 Alexander PE, Debono VB, Mammen MJ, et al. COVID-19 research has overall low methodological quality thus far: Case in point for chloroquine/hydroxychloroquine. Journal of Clinical Epidemiology 2020;

9. Leelakanok N, Holcombe AL, Lund BC, Gu X, Schweizer ML. Association between polypharmacy and death: A systematic review and meta-analysis. Journal of the American Pharmacists Association: JAPhA 57(6):729–738.e10.

10. MacBride-Stewart S, Guthrie B, Marwick C, Hurding S. National Therapeutic Indicators in Scotland and Financial Incentives. International Journal of Population Data Science 2019;4(3).

11. Edelman EJ, Gordon KS, Crothers K, et al. Association of Prescribed Opioids With Increased Risk of Community-Acquired Pneumonia Among Patients With and Without HIV. JAMA Internal Medicine 2019;179(3):297–304.

Wan Y, Li J, Shen L, et al. Enteric involvement in hospitalised patients with COVID-19 outside
 Wuhan. The Lancet Gastroenterology & Hepatology 2020;

13. Luo H, Fan Q, Xiao S, Chen K. Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists' effect on prescribing practice at a tertiary hospital. BMC health services research 2018;18(1):537.

 Pasina L, Novella A, Elli C, Nobili A, Ianes A. Overuse of proton pump inhibitors in nursing homes: An Italian multicenter observational study. Pharmacoepidemiology and Drug Safety 2020;29(4):461–6.

15. Ramirez E, Lei SH, Borobia AM, et al. Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital. Current Clinical Pharmacology 2010;5(4):288–97.

16. Weiner SG, Malek SK, Price CN. The Opioid Crisis and Its Consequences. Transplantation 2017;101(4):678–81.

17. de Abajo FJ, Rodríguez-Martín S, Lerma V, et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: A case-population study. Lancet (London, England) 2020;395(10238):1705–14.

n



Fig 1. Rate ratios (with standard errors) in a conditional logistic regression of severe COVID-19 on number of cardiovascular (BNF chapter 4) and non-cardiovascular drug classes dispensed

Number of drug classes	Controls (36948)	Cases (4272)	Rate ratio (95% CI)	<i>p</i> -value
Not resident	z in care home (34)	4013 controls,	2378 cases)	
0	5038~(15%)	172~(7%)		
1 to 3	11114 (33%)	449 (19%)	1.55 (1.29, 1.87)	3×10^{-6}
4 to 6	8518 (25%)	584~(25%)	2.97(2.47, 3.57)	1×10^{-30}
7 to 9	5102 (15%)	469(20%)	4.38(3.61, 5.32)	3×10^{-50}
10 to 12	2518 (7%)	328~(14%)	6.5 (5.3, 8.0)	1×10^{-69}
>12	1723~(5%)	376~(16%)	$10.8 \ (8.7, \ 13.2)$	1×10^{-111}
Care home n	residents (2935 co	ontrols, 1894 d	cases)	
0	40 (1%)	32 (2%)		
1 to 3	261 (9%)	167(9%)	$2.01 \ (0.87, \ 4.63)$	0.1
4 to 6	800(27%)	395~(21%)	$1.38 \ (0.62, \ 3.09)$	0.4
7 to 9	821 (28%)	574 (30%)	1.86(0.83, 4.17)	0.1
10 to 12	585 (20%)	425 (22%)	$2.02 \ (0.90, \ 4.55)$	0.09
>12	428~(15%)	301~(16%)	$1.91 \ (0.85, \ 4.30)$	0.1

 Table 1. Association of severe COVID-19 with number of non-cardiovascular drug classes dispensed, by care home residence

BNF subparagraph	Controls (17280)	$\begin{array}{c} \text{Cases} \\ (650) \end{array}$	Rate ratio	<i>p</i> -value
103050: Proton pump inhibitors	4670	232	1.84(1.52, 2.22)	4×10^{-10}
104020: Antimotility drugs	264	20	2.72(1.54, 4.81)	6×10^{-4}
105010: Aminosalicylates	149	15	3.42(1.78, 6.60)	2×10^{-4}
106040: Osmotic laxatives	1255	78	2.28(1.67, 3.11)	2×10^{-7}
401020: Anxiolytics	488	41	2.12(1.43, 3.16)	$2 imes 10^{-4}$
402010: Antipsychotic drugs	166	25	3.89(2.29, 6.62)	$5 imes 10^{-7}$
403010: Tricyclic and related	1042	64	1.85(1.35, 2.52)	1×10^{-4}
antidepressant drugs				
403040: Other antidepressant drugs	503	48	$2.68 \ (1.85, \ 3.88)$	2×10^{-7}
407010: Non-opioid analgesics and	4221	224	$2.01 \ (1.65, \ 2.45)$	4×10^{-12}
compound preparations				
407020: Opioid analgesics	1032	80	$2.32 \ (1.73, \ 3.13)$	3×10^{-8}
408010: Control of epilepsy	750	51	$2.26 \ (1.59, \ 3.20)$	5×10^{-6}
501012: Penicillinase-resistant	574	41	$2.26\ (1.52,\ 3.36)$	6×10^{-5}
501013. Broad-spectrum penicillins	1160	71	1 00 (1 47 2 60)	1×10^{-5}
501015. Dioad-spectrum pemeinins	1100	11	1.55 (1.41, 2.05)	1 × 10
603020: Use of corticosteroids	333	33	$3.36\ (2.11,\ 5.35)$	3×10^{-7}
901011: Oral iron	409	26	2.81 (1.66, 4.78)	1×10^{-4}
901020: Drugs used in megaloblastic	1023	56	2.10(1.48, 2.97)	3×10^{-5}
anaemias				
904020: Enteral nutrition	99	17	5.8(2.7, 12.2)	5×10^{-6}
906040: Vitamin D	1732	73	1.83(1.32, 2.55)	3×10^{-4}
1001010: Non-steroidal anti-inflammatory drugs	1454	86	1.65 (1.27, 2.14)	2×10^{-4}

Table 2. Univariate rate ratios for severe COVID-19 associated with dispensing of each BNF subparagraph code, restricted to those without a listed condition and not resident in a care home, filtered to show only drug classes with at least 50 exposed individuals and p < 0.001:

Table 3. Associations of severe COVID-19 with drug classes listed by Laporte and Healy (2020), restricted to those not resident in a care home. Adjusted rate ratios are based on a joint model with all drug classes in the table and SIMD quintile as covariates

			Univariate	Ð	Adjusted	
	Controls (34013)	Cases (2378)	Rate ratio $(95\% \text{ CI})$	<i>p</i> -value	Rate ratio $(95\% \text{ CI})$	<i>p</i> -value
103050.Proton pump inhibitors	$12805\ (38\%)$	1177 (49%)	$1.81 \ (1.66, \ 1.98)$	3×10^{-39}	$1.44\ (1.31,\ 1.58)$	8×10^{-1}
102000.Antispasmodic and other drugs altering gut motility	1232~(4%)	134~(6%)	$1.74 \ (1.44, \ 2.12)$	2×10^{-8}	$1.08\ (0.88,\ 1.33)$	0.4
304010. Antihistamines	$2571 \ (8\%)$	$265\ (11\%)$	$1.60\ (1.39,\ 1.85)$	4×10^{-11}	$1.30\ (1.12,\ 1.50)$	$5 imes 10^{-4}$
401010.Hypnotics	1401 (4%)	159(7%)	$1.75 \ (1.47, \ 2.10)$	$9 imes 10^{-10}$	$1.01 \ (0.83, 1.23)$	0.9
401020.Anxiolytics	1313 $(4%)$	185(8%)	$2.17\ (1.83,\ 2.57)$	3×10^{-19}	$1.25\ (1.04,\ 1.51)$	0.02
402010.Antipsychotic	529~(2%)	$151 \ (6\%)$	$4.14 \ (3.39, \ 5.07)$	1×10^{-43}	$2.79\ (2.23,\ 3.49)$	2×10^{-1}
402030.Drugs used for	(%0) 29	$10 \ (0\%)$	$2.53\ (1.26,\ 5.10)$	0.009	$0.94\ (0.44,\ 2.00)$	0.9
403010. Tricyclic and related antidepressant druss	2774~(8%)	269~(11%)	$1.58\ (1.38,\ 1.82)$	1×10^{-10}	$1.09\ (0.94,1.27)$	0.3
403030.Selective serotonin re-uptake inhibitors	$2929\ (9\%)$	$302\ (13\%)$	$1.60\ (1.40,\ 1.83)$	4×10^{-12}	$1.18\ (1.03,\ 1.36)$	0.02
403040.Other antidepressant drugs	1569~(5%)	$261\ (11\%)$	$2.71\ (2.34,\ 3.14)$	4×10^{-40}	$1.76\ (1.50,\ 2.07)$	4×10^{-13}
406000.Drugs used in nausea and vertigo	1804~(5%)	216~(9%)	$1.97\ (1.69,\ 2.31)$	$2 imes 10^{-17}$	$1.43\ (1.21,\ 1.69)$	$2 imes 10^{-5}$
407020.Opioid analgesics Gabapentinoids	$\begin{array}{c} 3385 \ (10\%) \\ 1751 \ (5\%) \end{array}$	$\begin{array}{c} 485 \ (20\%) \\ 253 \ (11\%) \end{array}$	$2.59\ (2.31,\ 2.90)\ 2.27\ (1.96,\ 2.63)$	1×10^{-59} 4×10^{-28}	$\begin{array}{c} 1.83 \ (1.61, \ 2.07) \\ 1.37 \ (1.16, \ 1.60) \end{array}$	1×10^{-2} 1×10^{-4}
Other drugs used for enilensy	758(2%)	100(4%)	1.83(1.47, 2.29)	7×10^{-8}	$1.34\ (1.06,\ 1.69)$	0.01
409020.Antimuscarinic drugs used in parkinsonism	31 (0%)	2 (%0)	2.85(1.21, 6.70)	0.02	$0.85 \ (0.35, \ 2.07)$	0.7
704020.Drugs for urinary frequency enuresis and incontinence	1631 (5%)	134~(6%)	$1.36\ (1.12,\ 1.65)$	0.002	$1.02 \ (0.84, \ 1.25)$	0.8
1001010.Non-steroidal anti-inflammatory drugs	$2401 \ (7\%)$	207~(9%)	$1.15\ (0.99,\ 1.35)$	0.07	$0.87\ (0.74,\ 1.02)$	0.08

Supplementary Tables

Table S1.	Association	of severe COV	/ID-19 with	number	of non-car	diovascular	drug classes $% \left({{\left({{{\left({{\left({\left({{\left({{\left({{\left($	dispensed,
in those not	t resident in	a care home h	y diagnosis	of at leas	st one liste	ed condition	1	

Number of	Controls (34013)	Cases (2378)	Rate ratio (95% CI)	p-value
drug classes				
No listed co	ndition $(17280 co$	ontrols, 650 ca	ses)	
0	4534~(26%)	125~(19%)		
1 to 3	7149 (41%)	229~(35%)	1.59 (1.25, 2.02)	1×10^{-4}
4 to 6	3565~(21%)	153(24%)	2.69(2.04, 3.55)	2×10^{-12}
7 to 9	1425 (8%)	79(12%)	$4.11 \ (2.88, \ 5.88)$	9×10^{-15}
10 to 12	458 (3%)	46 (7%)	7.3(4.6, 11.7)	3×10^{-17}
>12	149 (1%)	18 (3%)	7.2(3.8, 13.8)	3×10^{-9}
At least one	e listed condition	(16733 contro)	ls, 1728 cases)	
0	504 (3%)	47(3%)		
1 to 3	3965~(24%)	220(13%)	$0.62 \ (0.43, \ 0.89)$	0.01
4 to 6	4953 (30%)	431~(25%)	$1.01 \ (0.71, \ 1.43)$	1
7 to 9	3677~(22%)	390~(23%)	$1.33 \ (0.93, \ 1.90)$	0.1
10 to 12	2060~(12%)	282~(16%)	1.87 (1.29, 2.69)	$9 imes 10^{-4}$
>12	1574 (9%)	358 (21%)	2.95 (2.05, 4.25)	5×10^{-9}

	Controls (31024)	Cases (2081)	Rate ratio (95% CI)	p-value
Antipsychotic drugs				
Aripiprazole	38(0%)	12 (1%)	3.19(1.61, 6.33)	9×10^{-4}
Olanzapine	96 (0%)	18 (1%)	2.63(1.55, 4.49)	4×10^{-4}
Levomepromazine	27(0%)	17(1%)	9.9(4.7, 20.6)	1×10^{-9}
Risperidone	123(0%)	40 (2%)	4.90(3.26, 7.38)	3×10^{-14}
Haloperidol	18 (0%)	9 (0%)	8.8(3.3, 23.0)	1×10^{-5}
Chlorpromazine hydrochloride	26(0%)	7(0%)	3.00(1.28, 7.03)	0.01
Amisulpride	21 (0%)	4 (0%)	6.0(1.7, 21.4)	0.005
Drugs for nausea and vertigo				
Prochlorperazine	770 (2%)	59~(3%)	$1.36\ (1.02,\ 1.81)$	0.03
Cinnarizine	150 (0%)	12(1%)	$1.46\ (0.78,\ 2.71)$	0.2
Cyclizine	283 (1%)	44(2%)	2.74(1.93, 3.88)	2×10^{-8}
Metoclopramide hydrochloride	159 (1%)	24(1%)	2.60(1.62, 4.16)	7×10^{-5}
Betahistine dihydrochloride	368(1%)	17 (1%)	0.68(0.41, 1.13)	0.1
Domperidone	54(0%)	10 (0%)	$2.63\ (1.27,\ 5.43)$	0.009
Opioids				
Morphine	454 (1%)	121 (6%)	4.53 (3.58, 5.73)	2×10^{-36}
Codeine phosphate	567(2%)	82 (4%)	2.65(2.03, 3.46)	8×10^{-13}
Tramadol hydrochloride	1144 (4%)	119 (6%)	1.73(1.41, 2.13)	2×10^{-7}
Fentanyl	102 (0%)	14 (1%)	2.17(1.18, 4.00)	0.01
Buprenorphine	154(0%)	9 (0%)	1.18(0.57, 2.45)	0.6
Oxycodone	249(1%)	55(3%)	4.27 (3.05, 5.99)	3×10^{-17}
Gabapentinoids				
Gabapentin	974(3%)	115 (6%)	1.90 (1.54, 2.35)	2×10^{-9}
Lamotrigine	143(0%)	21 (1%)	2.22(1.37, 3.60)	0.001
Control of epilepsy				
Topiramate	34~(0%)	5(0%)	$1.96 \ (0.74, \ 5.17)$	0.2
Carbamazepine	176 (1%)	14 (1%)	1.17(0.67, 2.06)	0.6
Clonazepam	46 (0%)	10 (0%)	2.97(1.44, 6.11)	0.003
Levetiracetam	137(0%)	24(1%)	2.62(1.64, 4.17)	5×10^{-5}
Sodium valproate	106 (0%)	9 (0%)	1.00(0.50, 2.01)	1
Phenobarbital	20(0%)	4 (0%)	2.28(0.70, 7.39)	0.2
Phenytoin	49 (0%)	11 (1%)	3.08(1.54, 6.17)	0.001
Primidone	29(0%)	4 (0%)	$1.91 \ (0.64, \ 5.70)$	0.2
Lacosamide	19(0%)	2(0%)	$1.52 \ (0.34, \ 6.79)$	0.6

Table S2. Univariate associations of severe COVID-19 with drugs in four subparagraphs of BNF chapter 4, in those not resident in a care home and not treated for cancer in last year, filtered to retain rows with at least 20 exposed individuals

Exposure category	Controls (36948)	Cases (4272)	Rate ratio (95% CI)	<i>p</i> -value
Proton pump inhi	bitors			
Non-recent only	1048 (3%)	123 (3%)		
Recent only	1336~(4%)	208~(5%)	$1.33\ (1.05,\ 1.70)$	0.02
Antihistamines				
Non-recent only	766~(2%)	105 (2%)		
Recent only	553(1%)	102(2%)	$1.32 \ (0.98, \ 1.77)$	0.07
Anxiolytics				
Non-recent only	442~(1%)	113~(3%)		
Recent only	453~(1%)	157~(4%)	$1.36\ (1.03,\ 1.80)$	0.03
Tricyclic and relat	ed antidepres	sant drugs		
Non-recent only	446 (1%)	58(1%)		
Recent only	398~(1%)	52(1%)	$1.03 \ (0.69, \ 1.54)$	0.9
Drugs used in nau	sea and vertig	go		
Non-recent only	635~(2%)	87(2%)		
Recent only	610~(2%)	107~(3%)	$1.27 \ (0.93, \ 1.72)$	0.1
Opioid analgesics				
Non-recent only	696~(2%)	129~(3%)		
Recent only	779~(2%)	215~(5%)	$1.52\ (1.19,\ 1.95)$	9×10^{-4}
Antimuscarinic dr	ugs used in pa	arkinsonism		
Non-recent only	635~(2%)	87(2%)		
Recent only	610~(2%)	107~(3%)	$1.27 \ (0.93, \ 1.72)$	0.1
Drugs for urinary	frequency en	uresis and inco	ontinence	
Non-recent only	635~(2%)	87(2%)		
Recent only	610~(2%)	107~(3%)	$1.27 \ (0.93, \ 1.72)$	0.1

Table S3. Comparison of associations with exposure only in the most recent 120-day time window with exposure only in the previous 120-day time window (baseline category for rate ratios) for drug classes on the Laporte-Healy list with at least 500 cases and controls exposed only in the earlier time window

ent for prespecified co	variates					
			Univariate		Adjusted for cov	ariates
Average dose	Controls (36948)	Cases (4272)	Rate ratio (95% CI)	<i>p</i> -value	Rate ratio (95% CI)	<i>p</i> -value
Opioid-containing	analgesics (mg n	norphine equi	valent / day)			
Ages 0-74 years						
0	$12225 \ (91\%)$	$1075\ (79\%)$				
1-20	827~(6%)	$159\ (12\%)$	$2.24 \ (1.87, 2.69)$	$7 imes 10^{-18}$	1.95(1.60, 2.38)	$7 imes 10^{-11}$
21-50	$250\ (2\%)$	(5%)	3.19(2.42, 4.20)	$2 imes 10^{-16}$	2.98(2.22, 4.00)	4×10^{-13}
>50	170(1%)	54(4%)	$3.62\ (2.65,4.94)$	$7 imes 10^{-16}$	2.90(2.04, 4.11)	$3 imes 10^{-9}$
Ages $75+$ years						
0	$20241 \ (86\%)$	2302 (79%)				
1-20	$2287\ (10\%)$	$397\ (14\%)$	$1.55\ (1.38,\ 1.75)$	3×10^{-13}	$1.31 \ (1.14, \ 1.50)$	1×10^{-4}
21-50	602(3%)	117(4%)	1.75(1.42, 2.15)	$2 imes 10^{-7}$	$1.39\ (1.09,\ 1.76)$	0.007
>50	$346\ (1\%)$	100(3%)	2.72(2.16, 3.44)	4×10^{-17}	2.17(1.66, 2.84)	$2 imes 10^{-8}$
Proton pump inhi	bitors (defined d	aily doses / di	ay)			
Ages 0-74 years						
0	9442~(70%)	732~(54%)				
0.5	$1343 \ (10\%)$	$181 \ (13\%)$	$1.78 \ (1.50, \ 2.12)$	$9 imes 10^{-11}$	$1.75 \ (1.45, \ 2.12)$	$7 imes 10^{-9}$
1	1531 (11%)	$242 \ (18\%)$	2.13(1.81, 2.49)	$1 imes 10^{-20}$	1.88(1.57, 2.24)	$3 imes 10^{-12}$
1.5	(559 (5%))	120(9%)	$2.51 \ (2.03, \ 3.12)$	4×10^{-17}	$2.17\ (1.71,\ 2.76)$	$2 imes 10^{-10}$
2 or more	497(4%)	81(6%)	$2.19 \ (1.70, \ 2.80)$	$7 imes 10^{-10}$	$1.98\ (1.50,\ 2.60)$	$1 imes 10^{-6}$
Ages $75+$ years						
0	$13415\ (57\%)$	$1549\ (53\%)$				
0.5	$2834 \ (12\%)$	400(14%)	$1.25\ (1.11,\ 1.41)$	$3 imes 10^{-4}$	$1.35\ (1.18,\ 1.55)$	$2 imes 10^{-5}$
1	4120 (18%)	$545 \ (19\%)$	$1.15\ (1.04,\ 1.28)$	0.008	$1.13 \ (1.00, \ 1.28)$	0.05
1.5	$1884 \ (8\%)$	264 (9%)	$1.22\ (1.06,\ 1.41)$	0.006	$1.08\ (0.92,\ 1.28)$	0.3
2 or more	1223 (5%)	158(5%)	$1.11 \ (0.93, 1.32)$	0.3	$1.26\ (1.02,\ 1.54)$	0.03

Table S4. Associations of severe COVID-19 with dispensed average daily dose of opioids and proton pump inhibitors, with and without adjustme

			Univariate		Multivariat	je
	Controls (34013)	Cases (2378)	Rate ratio (95% CI)	<i>p</i> -value	Rate ratio (95% CI)	p-value
Cardiac glycosides	821 (2%)	94 (4%)	1.96(1.54, 2.48)	3×10^{-8}	1.10(0.84, 1.42)	0.5
Thiazides and related	$3869\ (11\%)$	177 (7%)	$0.72\ (0.61,\ 0.84)$	$6 imes 10^{-5}$	$0.86\ (0.73,\ 1.02)$	0.08
Loop diuretics	3969~(12%)	560 (24%)	$2.97\ (2.65,\ 3.34)$	$2 imes 10^{-76}$	$2.59\ (2.28,\ 2.95)$	$1 imes 10^{-47}$
Potassium-sparing diuretics and aldosterone antagonists	706(2%)	96(4%)	2.10(1.66, 2.64)	3×10^{-10}	$1.21\ (0.94,\ 1.55)$	0.1
Potassium sparing diuretics and compounds	71 (0%)	5(0%)	$1.17\ (0.45,\ 3.00)$	0.8	$1.02\ (0.39,\ 2.69)$	1
Drugs for arrhythmias Beta-adrenoceptor	$\begin{array}{c} 171 \ (1\%) \\ 8291 \ (24\%) \end{array}$	$\begin{array}{c} 19 \ (1\%) \\ 688 \ (29\%) \end{array}$	$\begin{array}{c} 1.71 \ (1.04, \ 2.80) \\ 1.40 \ (1.27, \ 1.55) \end{array}$	$\begin{array}{c} 0.04 \\ 1 \times 10^{-11} \end{array}$	$\begin{array}{c} 1.21 \ (0.73, \ 2.01) \\ 1.07 \ (0.95, \ 1.20) \end{array}$	$0.5 \\ 0.3$
blocking drugs Centrally-acting antihymertensiya drugs	20 (0%)	$3 \ (0\%)$	$0.72\ (0.22,\ 2.32)$	0.6	$0.69\ (0.21,\ 2.28)$	0.5
Alpha-adrenoceptor blocking drugs	1287~(4%)	70(3%)	$0.89\ (0.69,\ 1.14)$	0.4	$0.80\ (0.62,\ 1.04)$	0.09
Angiotensin-converting enzyme inhibitors	8039~(24%)	524~(22%)	$0.97\ (0.87,\ 1.08)$	0.6	$0.78\ (0.69,\ 0.88)$	3×10^{-5}
Angiotensin-II receptor antagonists	$3801\ (11\%)$	221~(9%)	$0.88 \ (0.76, \ 1.02)$	0.09	$0.72\ (0.61,\ 0.84)$	4×10^{-5}
Nitrates	2848 (8%)	250(11%)	1.40(1.21, 1.62)	$6 imes 10^{-6}$	$0.98\ (0.83,\ 1.15)$	0.8
Calcium-channel blockers	8278(24%)	$526\ (22\%)$	$0.99\ (0.89,\ 1.10)$	0.8	$1.04\ (0.93,\ 1.17)$	0.5
Other antianginal drugs Peripheral vasodilators and related drugs	694 (2%) 95 (0%)	70 (3%) 8 (0%)	$1.56 \ (1.20, \ 2.04) $ $1.42 \ (0.66, \ 3.02)$	$0.001 \\ 0.4$	$\begin{array}{c} 1.12 \; (0.84, \; 1.49) \\ 1.21 \; (0.56, \; 2.62) \end{array}$	$0.4 \\ 0.6$
Parenteral anticoagulants	152(0%)	$23 \ (1\%)$	$2.31 \ (1.46, \ 3.67)$	4×10^{-4}	$2.07 \ (1.28, \ 3.33)$	0.003
Oral anticoagulants Antinlatelet dmiss	3873 (11%) 8829 (96%)	410 (17%) 601 (90%)	$1.88\ (1.66,\ 2.12)$ $1.98\ (1.16\ 1\ 19)$	7×10^{-24} $0 < 10^{-7}$	$1.50\ (1.29,\ 1.75)$ 1 30 (1 93 1 58)	2×10^{-6} 2×10^{-7}
Lipid-regulating drugs	14522 (43%)	1040 (44%)	1.20 (1.10, 1.42) 1.18 (1.08, 1.30)	3 imes 10 $4 imes 10^{-4}$	1.03 (1.23, 1.30) 1.01 (0.90, 1.13)	0.1×2

Table S5. Associations of severe COVID-19 with prescribed drugs in BNF chapter 2 by subparagraph code, restricted to those not resident in a car

chapter 10 by approved name, restricted to those not resident in a	
e COVID-19 in with prescribed drugs in BNF ch	rows with at least 50 exposed individuals
e S6. Associations of severe	home and filtered to retain 1
Tabl	care

			Univariate		Multivariat	e
	Controls (34013)	Cases (2378)	Rate ratio (95% CI)	<i>p</i> -value	Rate ratio $(95\% \text{ CI})$	<i>p</i> -value
Non-steroidal anti-inflamma	tory drugs (exclud	ling topical p	reparations)			
Diclofenac	255(1%)	23(1%)	$1.17\ (0.75,\ 1.81)$	0.5	$1.09\ (0.70,\ 1.69)$	0.7
Celecoxib	84(0%)	11(0%)	$2.12 \ (1.09, 4.10)$	0.03	$2.03\ (1.04,\ 3.95)$	0.04
Ibuprofen	$638\ (2\%)$	56(2%)	$1.23 \ (0.92, 1.63)$	0.2	$1.23\ (0.92,\ 1.63)$	0.2
Meloxicam	$133\ (0\%)$	4(0%)	$0.42 \ (0.15, 1.15)$	0.09	$0.43 \ (0.16, \ 1.18)$	0.1
Etodolac	74(0%)	(%0) 6	$1.51 \ (0.74, 3.10)$	0.3	$1.30\ (0.63,\ 2.68)$	0.5
Etoricoxib	78 (0%)	12(11%)	$1.94 \ (1.04, \ 3.63)$	0.04	1.70(0.90, 3.21)	0.1
Rheumatic disease suppress	unt drugs					
Hydroxychloroquine sulfate	$210 \ (1\%)$	$24\ (1\%)$	2.10(1.34, 3.28)	0.001	$1.70\ (1.05,\ 2.76)$	0.03
Methotrexate	329 $(1%)$	36(2%)	$1.87 \ (1.30, \ 2.68)$	$7 imes 10^{-4}$	$1.55\ (1.04,\ 2.29)$	0.03
Gout and hyperuricaemia						
Allopurinol	$1507 \ (4\%)$	177 (7%)	$1.80\ (1.51,\ 2.14)$	$3 imes 10^{-11}$	$1.75\ (1.47,\ 2.09)$	4×10^{-10}
Colchicine	$291 \ (1\%)$	$35 \ (1\%)$	1.66(1.15, 2.42)	0.008	$1.36\ (0.93,\ 2.00)$	0.1
Skeletal muscle relaxants						
Baclofen	(0%) (0%)	$28\ (1\%)$	$5.2\ (3.3,\ 8.2)$	3×10^{-12}	$5.1\ (3.2,8.1)$	6×10^{-12}